Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT Pharmaceuticals (FRA:2RY1) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China SXT Pharmaceuticals EBITDA Margin % Related Terms
China SXT Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2RY1 vs CABR, BFRI, BIOE: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China SXT Pharmaceuticals (FRA:2RY1) has a EBITDA Margin % of 59.95% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China SXT Pharmaceuticals and its competitors. According to the industry distribution chart, China SXT Pharmaceuticals ranks #915 out of 959 companies in the Drug Manufacturers industry, placing it in the top 95.4%.
Is China SXT Pharmaceuticals' EBITDA Margin % too high?
China SXT Pharmaceuticals' current EBITDA Margin % is 59.95%. The Drug Manufacturers industry median EBITDA Margin % is 12.49. China SXT Pharmaceuticals' value of 59.95% is 380% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #915 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' EBITDA Margin % compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #915 out of 959 companies for EBITDA Margin %. This places China SXT Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.49. China SXT Pharmaceuticals' value of 59.95% is 380% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current EBITDA Margin % of 59.95% is 380% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current EBITDA Margin % is 59.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY1) has a current EBITDA Margin % of 59.95%. The stock's GF Value™ is €1.16, compared to a current price of €0.04 — trading 96.9% below its estimated fair value. The current EBITDA Margin % is 59.95% and 380% above the Drug Manufacturers industry median of 12.49. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY1), the current EBITDA Margin % is 59.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (FRA:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €0.04 is trading 96.9% below its estimated GF Value™ of €1.16.
Key valuation signals for FRA:2RY1:
EBITDA Margin %: 59.95%
GF Value™: €1.16 vs. price of €0.04 (96.9% below fair value)
Industry Position: 380% above the Drug Manufacturers median (#915 of 959)
No single metric tells the full story. See the FRA:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score
Get the complete analysis for FRA:2RY1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY1 has been successfully added to your 
